JP2024533420A - 腎臓病の治療に用いられる５－（３，４－ジクロロフェニル）－ｎ－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシル）－６－（２，２，２－トリフルオロエトキシ）ニコチンアミドの固形形態 - Google Patents
腎臓病の治療に用いられる５－（３，４－ジクロロフェニル）－ｎ－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシル）－６－（２，２，２－トリフルオロエトキシ）ニコチンアミドの固形形態 Download PDFInfo
- Publication number
- JP2024533420A JP2024533420A JP2024515556A JP2024515556A JP2024533420A JP 2024533420 A JP2024533420 A JP 2024533420A JP 2024515556 A JP2024515556 A JP 2024515556A JP 2024515556 A JP2024515556 A JP 2024515556A JP 2024533420 A JP2024533420 A JP 2024533420A
- Authority
- JP
- Japan
- Prior art keywords
- diffraction pattern
- characteristic
- degrees
- crystalline form
- onset
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111049581.4 | 2021-09-08 | ||
| CN202111049581.4A CN115772123A (zh) | 2021-09-08 | 2021-09-08 | 固体形式 |
| US202163243813P | 2021-09-14 | 2021-09-14 | |
| US63/243,813 | 2021-09-14 | ||
| PCT/US2022/042905 WO2023039063A1 (en) | 2021-09-08 | 2022-09-08 | Solid form of 5-(3,4-dichlorophenyl)-n-((1r,2r)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide for use in treating kidney diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533420A true JP2024533420A (ja) | 2024-09-12 |
| JP2024533420A5 JP2024533420A5 (https=) | 2025-09-12 |
Family
ID=83594511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515556A Pending JP2024533420A (ja) | 2021-09-08 | 2022-09-08 | 腎臓病の治療に用いられる５－（３，４－ジクロロフェニル）－ｎ－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシル）－６－（２，２，２－トリフルオロエトキシ）ニコチンアミドの固形形態 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11814354B2 (https=) |
| EP (1) | EP4399201A1 (https=) |
| JP (1) | JP2024533420A (https=) |
| AU (1) | AU2022342069A1 (https=) |
| CA (1) | CA3231117A1 (https=) |
| TW (1) | TW202334088A (https=) |
| WO (1) | WO2023039063A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US20120101282A1 (en) | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| WO2014180741A1 (en) | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
-
2022
- 2022-09-07 US US17/939,203 patent/US11814354B2/en active Active
- 2022-09-08 AU AU2022342069A patent/AU2022342069A1/en active Pending
- 2022-09-08 EP EP22785823.0A patent/EP4399201A1/en active Pending
- 2022-09-08 JP JP2024515556A patent/JP2024533420A/ja active Pending
- 2022-09-08 WO PCT/US2022/042905 patent/WO2023039063A1/en not_active Ceased
- 2022-09-08 TW TW111134009A patent/TW202334088A/zh unknown
- 2022-09-08 CA CA3231117A patent/CA3231117A1/en active Pending
-
2023
- 2023-10-11 US US18/484,722 patent/US12134599B2/en active Active
-
2024
- 2024-09-27 US US18/898,885 patent/US20250263378A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250263378A1 (en) | 2025-08-21 |
| WO2023039063A1 (en) | 2023-03-16 |
| TW202334088A (zh) | 2023-09-01 |
| US11814354B2 (en) | 2023-11-14 |
| CA3231117A1 (en) | 2023-03-16 |
| US20240300895A1 (en) | 2024-09-12 |
| AU2022342069A1 (en) | 2024-03-14 |
| US20230242485A1 (en) | 2023-08-03 |
| EP4399201A1 (en) | 2024-07-17 |
| US12134599B2 (en) | 2024-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7797575B2 (ja) | ７ｈ－ピロロ［２，３－ｄ］ピリミジンｊａｋ－阻害剤 | |
| AU2018373122A1 (en) | Crystalline forms of N-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| KR20170125893A (ko) | 니코틴아미드 리보사이드의 결정 형태 | |
| JP2022502500A (ja) | 補体因子ｄ阻害剤の形態 | |
| KR20220019772A (ko) | 2,4,6-트리플루오로-n-[6-(1-메틸-피페리딘-4-카르보닐)-피리딘-2-일]-벤즈아미드 헤미숙시네이트의 대규모 제조를 위한 방법 및 중간체, 및 2,4,6-트리플루오로-n-[6-(1-메틸-피페리딘-4-카르보닐)-피리딘-2-일]-벤즈아미드 아세테이트의 제조 | |
| CN105189513A (zh) | 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态 | |
| JP2014144916A (ja) | ２−アシルアミノチアゾール化合物の結晶 | |
| CA3031343C (en) | Salts of 2,6-Dimethylpyrimidone derivatives and their uses | |
| US20250263378A1 (en) | Solid forms | |
| US20240199645A1 (en) | Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine | |
| US20240368185A1 (en) | Macrocyclic azolopyridines | |
| CN102190656B (zh) | 含有五元杂环的噁唑烷酮抗菌素 | |
| CN115772123A (zh) | 固体形式 | |
| CA2934456C (en) | Fused heterocyclic compounds as ion channel modulators | |
| US20250243242A1 (en) | Levodopa tyrosine polymorphs | |
| WO2026008074A1 (zh) | 补体因子b抑制剂的晶型、其制备方法及用途 | |
| WO2025101874A1 (en) | Crystalline salt forms of the tyrosine kinase inhibitor ecf506 | |
| HK1225728A1 (en) | Fused heterocyclic compounds as ion channel modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250904 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250904 |